RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All EMA (EU) updates
EMA (EU)
GUIDANCE FINAL
Draft guideline on the clinical requirements for medicines intended for the treatment of thalassaemia
Published: 9/24/2026Detected: 9/24/2026

Summary preview

Sets out EMA CHMP clinical evidence expectations for medicines for thalassaemia, including how confirmatory efficacy/safety studies should be designed, what patient/genotype populations should be targeted, and which…

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
hematology
pediatrics
clinical
safety
labeling
manufacturing
quality
#thalassaemia
#alpha-thalassaemia
#beta-thalassaemia
#transfusion-dependent

Official Source Document
Source Verified

Access the original document directly from EMA.

View Official Document

More from EMA (EU)

  • Mandatory use of ISO/ICH E2B(R3) individual case safety reporting in the EU: hands-on training course using the EudraVigilance system10/12/2026
  • First European Medicines Agency (EMA) - International Society for Cell and Gene Therapy (ISCT) bilateral meeting10/12/2026
  • Q&A clinic on eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) service - October 202610/8/2026
  • PMS Q&A Clinic on Product User Interface (PUI) and Application Programming Interface (API) – October 202610/8/2026
  • SPOR and XEVMPD status update webinar - Q4 202610/7/2026

Get EMA (EU) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
#non-transfusion-dependent
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.